The new treatment with ozanimod (also known as zeposia) will benefit over 12,000 adults who suffer from moderate to severe active ulcerative colitis (UC).
NICE has said it is unable to recommend NHS use of AstraZeneca's Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker.
The EMA's human medicines committee (CHMP) has recommended authorisation of two COVID-19 vaccines from Moderna and Pfizer/BioNTech that include sequences coding for Omicron spike protein as
German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP)
UK medtech company Brainomix has claimed its first national contract – from Hungary – for its artificial intelligence-based platform used to improve diagnosis and treatment of people with s
Sanofi now has approval on both sides of the Atlantic for Xenpozyme – its enzyme replacement therapy for rare disease acid sphingomyelinase deficiency (ASMD) – after getting a green light f
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.